Patents Assigned to Bristol-Myers
  • SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS
    Publication number: 20140135318
    Abstract: Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: May 23, 2012
    Publication date: May 15, 2014
    Applicant: Bristol-Myers Squibb Company
    Inventors: Robert M. Borzilleri, Zhen-Wei Cai, Andrew J. Tebben, Heidi L. Perez, Liping Zhang, Gretchen M. Schroeder, Donna D. Wei
  • Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule
    Patent number: 8722632
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as Sjogren's syndrome, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: May 13, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • Selective NR2B antagonists
    Patent number: 8722670
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: May 13, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dalton King, Richard E. Olson, John E. Macor, Imadul Islam, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier
  • Compounds for the treatment of hepatitis C
    Patent number: 8722688
    Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: May 13, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Kyle E. Parcella, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, John F. Kadow, Andrew Nickel
  • PYRIDONE/HYDROXYPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS
    Publication number: 20140128365
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: enantiomers, diastereomers, solvates, salts, tautomers or prodrugs thereof wherein, A, W, X, Y and R1 are defined herein.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 8, 2014
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jeffrey A. Robl, Shung C. Wu, David S. Yoon
  • Cyclic protein tyrosine kinase inhibitors
    Patent number: 8716323
    Abstract: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: May 6, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jagabandhu Das, Ramesh Padmanabha, Ping Chen, Derek J. Norris, Arthur M. P. Doweyko, Joel C. Barrish, John Wityak
  • Compound for the treatment of hepatitis C
    Patent number: 8716275
    Abstract: The present invention provides (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1 -methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl) carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide (formula I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compound. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: May 6, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zhizhen Barbara Zheng, Stanley D'Andrea
  • Fully human antibodies against human 4-1BB
    Patent number: 8716452
    Abstract: Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: May 6, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Maria Jure-Kunkel, Laura J. Hefta, Marc Santoro, Subinay Ganguly, Edward L. Halk
  • Five-membered heterocycles useful as serine protease inhibitors
    Patent number: 8716492
    Abstract: The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: May 6, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jon J. Hangeland, Mimi L. Quan, Joanne M. Smallheer, Gregory S. Bisacchi, James R. Corte, Todd J. Friends, Zhong Sun, Karen A. Rossi, Cullen L. Cavallaro
  • Pharmaceutical formulations containing an SGLT2 inhibitor
    Patent number: 8716251
    Abstract: Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: May 6, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Dilbir S. Bindra, Mandar V. Dali, Prakash V. Parab, Jatin M. Patel, Li Tao, Ravindra W. Tejwani, Nipa Vatsaraj, Yongmei Wu
  • Crystal Forms of Saxagliptin and Processes for Preparing Same
    Publication number: 20140121155
    Abstract: Physical crystal structures of a compound of the formula I: are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
    Type: Application
    Filed: December 27, 2013
    Publication date: May 1, 2014
    Applicant: Bristol-Myers Squibb Company
    Inventors: Jack Z. Gougoutas, Mary F. Malley, John D. DiMarco, Xiaotian S. Yin, Chenkou Wei, Jurong Yu, Truc Chi Vu, Gregory Scott Jones, Scott A. Savage
  • Enediyne compounds, conjugates thereof, and uses and methods therefor
    Patent number: 8709431
    Abstract: Enediyne compounds having a structure according to formula (I), where R0, R2, R3, R4, R5, R6, and R7 are defined herein, can be used in chemotherapeutic drugs, especially in conjugates, for the treatment of diseases such as cancer.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: April 29, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Naidu S. Chowdari, Sanjeev Gangwar, Bilal Sufi
  • Compounds for the reduction of ?-amyloid production
    Patent number: 8710061
    Abstract: The present disclosure provides a series of compounds of the formula (I) which modulate ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by ?-amyloid peptide (?-AP) production.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: April 29, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kenneth M. Boy, Jason M. Guernon, John E. Macor, Richard E. Olson, Jianliang Shi, Lorin A. Thompson, III, Yong-Jin Wu, Li Xu, Yunhui Zhang, Dmitry S. Zuev
  • Diaminocyclohexane compounds and uses thereof
    Patent number: 8710049
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 receptor and may be used for the treatment and prophylaxis of various diseases and conditions.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: April 29, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: William R. Ewing, Yeheng Zhu, Chongqing Sun, Yanting Huang, Maheswaran Sivasamban Karatholuvhu
  • Hepatitis C virus inhibitors
    Patent number: 8710229
    Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: April 29, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alan Xiangdong Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Yan Chen
  • LACTAM-CONTAINING COMPOUNDS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS
    Publication number: 20140113892
    Abstract: The present application describes lactam-containing compounds and derivatives thereof of Formula I: P4-P-M-M4??I or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Type: Application
    Filed: May 10, 2013
    Publication date: April 24, 2014
    Applicant: Bristol-Myers Squibb Company
    Inventors: Donald J.P. Pinto, Mimi L. Quan, Michael J. Orwat, Yun-Long Li, Wei Han, Jennifer X. Qiao, Patrick Y.S. Lam, Stephanie L. Koch
  • FC FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS
    Publication number: 20140113370
    Abstract: The application provides Fc fusion proteins having novel arrangements. In one embodiment, the application provides Fc fusion proteins comprising a 10Fn3 domain. In another embodiment, the application provides Fc fusion proteins comprising linkers derived from the naturally occurring C-terminal tail regions of membrane bound or secretory immunoglobulins.
    Type: Application
    Filed: April 13, 2012
    Publication date: April 24, 2014
    Applicant: Bristol-Myers Squibb Company
    Inventors: Ray Camphausen, Amna Saeed-Kothe, Jonathan Davis, Tracy S. Mitchell
  • Aryl ether-base kinase inhibitors
    Patent number: 8703953
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: April 22, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, John E. Macor, Joanne J. Bronson, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
  • Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule
    Patent number: 8703718
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as juvenile rheumatoid arthritis, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 22, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • Compounds for the treatment of hepatitis C
    Patent number: 8697706
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: April 15, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Qian Zhao, Paul Michael Scola